LOS ANGELES, Sept. 4, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or "the Company") (NASDAQ: EXEL) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Exelixis reported its Q2 2025 financial results on July 28, 2025. The Company repo ...

Company Overview - Exelixis is a cancer-focused commercial company dedicated to improving the standard of care in cancer treatment for patients [1] - The company has a leading molecule in kidney cancer called CABOMETYX (cabozantinib), supported by strong data and a robust commercial platform [1] Recent Developments - The company launched a new indication for NET (neuroendocrine tumors) at the end of Q1, with the official launch occurring in Q2 [2] - Exelixis aims to expand beyond CABOMETYX by building a pipeline of franchise molecules, leveraging learnings from CABOMETYX over the past decade [2] - The next molecule in development is zanzolitinib, which is currently in various pivotal trials, alongside a deep pipeline of both small molecules [2]

Exelixis (EXEL) Conference September 03, 2025 03:15 PM ET Company ParticipantsMichael Morrissey - CEO, President & DirectorConference Call ParticipantsDavid Lebowitz - Senior Research Analyst - BiotechnologyDavid LebowitzFor being here today at the two thousand twenty five Citi Biopharma Conference in Boston. Happy to have with us this afternoon our good friends from Exelixis, Michael. I guess you could just introduce yourself and the company. I'm sure sure anyone listening to this already knows who you are ...

Question-and-Answer SessionWell, good to hear that. And maybe just to kind of level set us, kind of just give us the state of the business here in terms of what's going on at Exelixis, and we have obviously plenty of questions to dig into, but maybe just set us up and then we'll move on from there.Michael MorrisseyCEO, President & Director For sure. Before I begin, let me just remind you, I'll be making forward-looking statements. So please see our SEC filings for a description of the risks that we face in ...

Exelixis (EXEL) FY 2025 Conference September 03, 2025 12:45 PM ET Company ParticipantsMichael Morrissey - CEO, President & DirectorConference Call ParticipantsDerek Archila - MD, Co-Head of Therapeutics Research & Senior Biotechnology AnalystMichael MorrisseyGood, busy. Yes, great schedule and there's another meeting going on today.Derek ArchilaAnd there are lots of lots of fun stuff. Yes, it's good.Michael MorrisseyWell, thanks for having us. Great to be here.Derek ArchilaAll right, everyone. I think we'll ...

Exelixis (EXEL) FY 2025 Conference September 03, 2025 12:45 PM ET Speaker0Good, busy. Yes, great schedule and there's another meeting going on today.Speaker1And there are lotsSpeaker0of lots of fun stuff. Yes, it's good. Well, thanks for having us. Great to be here.Speaker1All right, everyone. I think we'll get started here with the first session after lunchtime. But my name is Derek Archila. I'm one of the senior biotech analysts here at Wells. Very excited to have Exelixis and with us today, Michael Morri ...

Core Insights - Exelixis' lead drug, Cabometyx, has received FDA approval for label expansion to treat adult and pediatric patients aged 12 and older with previously treated, unresectable, locally advanced or metastatic well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors (NET) in March 2025, marking a significant advancement for the company [1][10] Product Overview - Cabometyx is the first and only systemic treatment FDA approved for previously treated NET, applicable regardless of primary tumor site, grade, somatostatin receptor expression, and functional status [2] - The drug is noted as the first broadly applicable new oral small molecule therapy for NET in nine years [2] Market Demand and Performance - Initial uptake for Cabometyx's new indication is strong, capturing 35% of the new patient share for oral therapies in this indication, with demand just over 4% of total demand for cabozantinib in Q2 [3][10] - Exelixis expects Cabometyx to be widely used across various patient and tumor characteristics, including those with NET from the pancreas, GI tract, and lung [5] Regulatory Approvals - In July, Exelixis announced that its partner Ipsen received regulatory approval for Cabometyx for adult patients with unresectable or metastatic well-differentiated extra-pancreatic and pancreatic NET in the EU [4] Competitive Landscape - Cabometyx faces competition from Novartis' Lutathera, which is also used for treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs) [6] - In the renal cell carcinoma (RCC) space, Cabometyx competes with Merck's Keytruda and Inlyta, as well as Merck's Welireg [7][8] Financial Performance - Exelixis shares have gained 13.8% year-to-date, outperforming the industry growth of 4% [9][10] - The company's valuation is considered high, with a price/sales ratio of 4.07x forward sales, above its mean of 3.64x and the biotech industry's 1.58x [11] Earnings Estimates - The bottom-line estimate for 2025 has increased from $2.65 to $2.68, while the estimate for 2026 has decreased from $3.13 to $3.08 over the past 30 days [12]

Group 1 - The article discusses Stephen's background as a Registered Nurse (RN) and an MBA, highlighting his unique approach to analyzing healthcare and tech stocks through the "Dizzy Framework" [1] - The "Dizzy Framework" is designed to mitigate common behavioral errors in investment, such as chasing market noise and adhering too rigidly to prior beliefs, emphasizing the importance of quality and timing of information [1] - Influences on Stephen's investment philosophy include concepts from "Superforecasting" and "Fooled by Randomness," which inform his disciplined and patient investment approach [1]

Core Insights - Exelixis (EXEL) has been actively repurchasing shares to enhance shareholder value, with a total authorization of $1 billion for buybacks through 2025 [1][6] - The company has successfully reduced its outstanding shares from 326.3 million to 284.4 million as of June 30, 2025, following its share repurchase initiatives [2][6] - EXEL's stock has outperformed the biotech industry, gaining 13.4% year-to-date compared to the industry's 3.6% growth [5] Share Repurchase Programs - In August 2024, EXEL's board authorized a stock repurchase program to buy back up to $500 million of common stock before December 31, 2025 [1] - An additional $500 million repurchase was authorized in February 2025, bringing the total repurchase authorization to $1 billion [2] - As of June 30, 2025, EXEL had repurchased $796.3 million of its common stock at an average price of $36.69 per share [2][6] Financial Position - At the end of Q2 2025, EXEL reported cash and cash equivalents and marketable securities totaling $791 million, indicating a strong cash position to meet its repurchase targets [3] - The company’s average buyback price of $36.69 per share has contributed to a significant reduction in shares outstanding [6] Industry Context - Other major pharmaceutical and biotech companies, such as Regeneron and Novartis, are also engaging in share buybacks to enhance shareholder value [3][4] - Regeneron repurchased shares worth $1.070 billion, while Novartis repurchased 48.8 million shares for $5.3 billion in the first half of 2025 [4] Valuation Metrics - EXEL's shares are currently trading at a price/sales ratio of 4.07x forward sales, which is higher than its historical mean of 3.64x and the biotech industry's average of 1.58x, indicating a potentially expensive valuation [8] - The bottom-line estimate for 2025 has increased from $2.64 to $2.68, while the estimate for 2026 has slightly decreased from $3.13 to $3.09 [9]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Exelixis, Inc. and its officers or directors [1] Financial Performance - On July 28, 2025, Exelixis reported second-quarter financial results, revealing net product revenues for cabozantinib were approximately 2% below the consensus estimate of $531.3 million [3] - Following the announcement, Exelixis's stock price dropped by $7.45 per share, or 16.78%, closing at $36.94 per share on July 29, 2025 [3] Clinical Development Update - Exelixis decided not to proceed to the phase 3 portion of the STELLAR-305 study in advanced squamous cell carcinoma of the head and neck due to emerging competition and assessment of other commercial opportunities [3]